KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $5.5 million.

  • Recursion Pharmaceuticals' Change in Accured Expenses fell 226.52% to -$8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.7 million, marking a year-over-year decrease of 473.76%. This contributed to the annual value of $5.5 million for FY2024, which is 17.86% down from last year.
  • Recursion Pharmaceuticals' Change in Accured Expenses amounted to $5.5 million in FY2024, which was down 17.86% from $6.7 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Change in Accured Expenses registered a high of $12.8 million during FY2021, and its lowest value of -$576,000 during FY2022.
  • Over the past 3 years, Recursion Pharmaceuticals' median Change in Accured Expenses value was $5.5 million (recorded in 2024), while the average stood at $3.9 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Change in Accured Expenses plummeted by 104.51% in 2022, and later skyrocketed by 1,266.49% in 2023.
  • Recursion Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $4.1 million in 2020, then surged by 209.58% to $12.8 million in 2021, then slumped by 104.51% to -$576,000 in 2022, then spiked by 1,266.49% to $6.7 million in 2023, then fell by 17.86% to $5.5 million in 2024.